| |
著者: N Ishiguro, R Oyamada, Y Nasuhara, T Yamada, T Miyamoto, S Imai, K Akizawa, T Fukumoto, S Iwasaki, H Iijima, K Ono
雑誌名: J Hosp Infect. 2016 Oct;94(2):150-3. doi: 10.1016/j.jhin.2016.05.012. Epub 2016 May 25.
Abstract/Text
Inpatients who had been in close contact with patients with influenza were given oseltamivir [75mg capsules once daily for adults or 2mg/kg (maximum of 75mg) once daily for children] for three days as postexposure prophylaxis (PEP). The index patients with influenza were prescribed a neuraminidase inhibitor and were discharged immediately or transferred to isolation rooms. The protective efficacy of oseltamivir for three days was 93% overall [95% confidence interval (CI) 53-99%; P=0.023] and 94% for influenza A (95% CI 61-99%; P=0.017), which is comparable to that of seven- to 10-day regimens of oseltamivir as PEP.
Copyright © 2016 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.
PMID 27346624 J Hosp Infect. 2016 Oct;94(2):150-3. doi: 10.1016/j.jhin.2016.05.012. Epub 2016 May 25.
|
